The Reject Pile

Proteomics: the field that almost didn't happen.

Down, Down

Numbers from the US National Institutes of Health indicate that 2013 saw fewer new awards and lower success rates.

This Week in Science

In Science this week: RNAi screen for genes involved in squamous cell carcinoma, and more.

Getting to that Point

Illumina announced earlier this week that its new platform could sequence a human genome for $1,000.

Second Chance for 23andMe

Is 23andMe's test likely to lead to unnecessary follow-up procedures? One writer says no.

Genetic Preview

Fetal whole-genome sequencing offers parents a peek into their kid's disease risk.

This Week in Nature

In Nature this week: migratory locust draft genome, and more.

Outlasting Past Fraud

The perpetrator of the great cloning fraud seeks a sort of scientific redemption.

This Week in Cell

In Cell this week: info in oocytes, fruit fly phenotypes, and influencing gene regulation.

Drug Fail

A more inclusive study of drug failure rates paints a gloomy picture.

Testing Decisions

A little education about genetic testing may help individuals decide whether or not to be tested.

Trusting Consumer Genomics

Do 23andMe's foibles signify a rocky road for DTC genomics?

Ownership Rights Online

Science publishers crack down on researchers' give-aways.